New drug aims to calm stubborn hives triggered by cold or scratching

NCT ID NCT07181369

Recruiting now Symptom relief Sponsor: Granular Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a single dose of an experimental drug called GTX-B001 in healthy people and those with chronic inducible urticaria—a condition where cold or scratching causes painful hives. The main goal is to check safety and how the body handles the drug. About 72 participants will take part, with some receiving the drug and others a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic inducible urticaria cold urticaria familial dermatographia skin disorder urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC INDUCIBLE URTICARIA COLD URTICARIA HEALTHY SUBJECTS SYMPTOMATIC DERMOGRAPHISM

Contacts and locations

Show contact details

Locations

Charité Research Organization gmbh
RECRUITING

Berlin, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••
Fraunhofer Institute For Translational Medicine And Pharmacology
NOT_YET_RECRUITING

Berlin, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••